

MSB-7267

AMENDMENTS TO THE CLAIMS

12. (Currently Amended) A stable lyophilized pharmaceutical composition comprising approximately 1 to 4 milligrams per milliliter of a ~~wild-type~~ human IL-2 mutein and a stabilizing mixture comprising histidine, glycine, and sucrose, wherein said human IL-2 mutein consists of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagine at position 88 in the wild-type human IL-2 with the amino acid arginine.

13. (Previously amended) The stable lyophilized composition of claim 12, wherein the histidine is present at approximately 0.06 -1.8 % measured by weight.

14. (Previously amended) The stable lyophilized composition of claim 12, wherein the glycine is present at approximately 1-3 % measured by weight.

15. (Previously amended) The stable lyophilized composition of claim 12, wherein the sucrose is present at approximately 0.5-3 % measured by weight.

16. (Previously amended) The stable lyophilized composition of claim 12 in aqueous form having a pH ranging from about 5.0 to 6.5.

MSB-7267

17. (Previously amended) A stable lyophilized pharmaceutical composition; which upon aqueous reconstitution comprises the following:

1.0 - 4.0 mg/ml of a human IL-2 mutein consisting of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagine at position 88 in the wild-type human IL-2 with the amino acid arginine,

and

| | |
|-----------|------------------|
| Histidine | 0.08 -1.6 % wt, |
| NaCl | 0 - 0.9 wt % |
| Sucrose | 1 - 10 % wt, and |
| Glycine | 0 - 3% wt at a |
| pH of | 5 - 6.5 . |